

1 **Separation of newly replicated bacterial chromosomes: the role of**
2 ***Escherichia coli* Topoisomerase IV**

3

4 Emily Helgesen^{1,2*}, Frank Sætre^{1,3} and Kirsten Skarstad¹

5 ¹ Department of Microbiology, Oslo University Hospital, Oslo, Norway

6 ² Department of Clinical and Molecular Medicine, Faculty of Medicine and Health
7 Sciences, Norwegian University of Science and Technology, Trondheim, Norway

8 ³ Department of Pathology, Institute of Clinical Medicine, University of Oslo, Oslo,
9 Norway

10

11

12 *Corresponding author

13

14 Mailing address:

15 ¹Department of Microbiology, Molecular Microbiology, Oslo University Hospital, p.o.
16 box 4950, 0424 Oslo, Norway.

17

18 Email: Emily.Helgesen@rr-research.no

19 Phone: +47 23013902

20

21

22 Running title: Separation of newly replicated bacterial chromosomes

23

24 Keywords: Topoisomerase IV, precatenanes, DNA replication, SeqA

25

26

27

28

29

30

31

32

33

34 **Abstract**

35

36 Topoisomerase IV (TopoIV) is a vital bacterial enzyme which disentangles newly
37 replicated DNA and enables segregation of daughter chromosomes. In bacteria, DNA
38 replication and segregation are concurrent processes. This means that TopoIV must
39 continually remove inter-DNA linkages during replication. There exists a short time lag
40 of about 5-10 minutes between replication and segregation in which the daughter
41 chromosomes are intertwined. Exactly where TopoIV binds during the cell cycle has
42 been the subject of much debate. We show here that TopoIV localizes to the origin
43 proximal side of the fork trailing protein SeqA and follows the movement pattern of the
44 replication machinery in the cell.

45

46 **Introduction**

47 Proper segregation of newly replicated DNA is essential for the viability and genetic
48 stability of all cell types. Due to the superhelical nature of DNA molecules, topology
49 challenges are inevitable during the process of DNA replication, as the template strands
50 are separated and duplicated. More specifically, tension arises in front of the replication
51 machinery (hereafter called the replication fork) as the parental DNA strands are pulled
52 apart, which results in the formation of positive supercoils (overwinding)^{1,2}. Some of
53 these positive supercoils may diffuse towards the newly replicated DNA molecules
54 behind the replication fork, and the replication fork most likely rotates to alleviate some
55 of the topology tension piling up ahead³. As a consequence, the newly replicated DNA
56 molecules become intertwined, and this type of entanglement is typically referred to as
57 precatenanes¹⁻⁴. Without the removal of precatenane linkages it becomes impossible for
58 the cell to segregate the DNA prior to cell division. Highly specific mechanisms
59 therefore exist to resolve the topological issues that arise during DNA replication, and at
60 the core of these mechanisms we find the enzymes categorized as type II
61 topoisomerases².

62 In *Escherichia coli* two type II topoisomerases are involved in enabling both
63 DNA replication and timely DNA segregation, namely Gyrase and Topoisomerase IV
64 (TopoIV). Both of these enzymes work by first performing a transient double strand
65 break in one molecule, then leading a second DNA duplex through the cut and lastly,
66 resealing the cut. They are heterotetrameric structures consisting of GyrA and GyrB
67 subunits or ParC and ParE subunits for Gyrase and TopoIV, respectively. The
68 GyrA/ParC subunit contains the DNA binding and catalytical properties of the enzyme,
69 whereas ATP binding resides in GyrB/ParE⁵. It is now generally well recognized that
70 Gyrase acts in front of the replication fork to remove excess positive supercoiling to
71 support fork progression, whereas TopoIV mainly removes precatenane linkages after
72 replication to facilitate DNA segregation⁶⁻⁹. However, there has been much debate
73 concerning the precise timing and localization of TopoIV action. It has been suggested
74 that TopoIV activity is limited to the D-period (when a round of DNA replication is
75 completed, see supplementary figure 1) and that TopoIV localizes mainly at the
76 terminus¹⁰. It has also been indicated that the catalytically active TopoIV molecules
77 bind in clusters at the origins, where they are recruited and stimulated by MukB, an
78 SMC (structural maintenance of chromosomes) protein¹¹⁻¹³. Moreover, there is a time
79 lag of 5-10 minutes between replication of the DNA and segregation of the newly

80 replicated DNA, which is termed the “cohesion period”^{6,8,9,14}. Whether this means that
81 TopoIV does not immediately gain access to the DNA after replication (i.e. that
82 precatenanes hold the homologous DNA together), or if other factors such as proteins
83 bridging the DNA is causing this delay, is not completely understood.

84 In this work we have sought to elucidate the localization and movement of
85 TopoIV with respect to the replication fork and a fork-trailing protein named SeqA.
86 SeqA is a negative modulator of replication initiation, which binds to newly replicated,
87 hemimethylated GATC-sites¹⁵⁻¹⁷. SeqA forms multimeric structures which trail the
88 replication forks dynamically, always binding to the newest DNA¹⁸⁻²¹. The SeqA-DNA
89 complexes are large and typically encompass 100 kb of DNA. We have previously
90 found that the SeqA multimer binds at a distance from the replisome (on average 200-
91 300 nm)²². The newly replicated DNA molecules were found to be kept close together
92 on this stretch, i.e. they were cohesed. The localization of the cohesed DNA and the
93 replisomes in the cell were visualized by utilizing fluorescently tagged SeqA (SeqA-
94 YFP) and replisome proteins (SSB-CFP), respectively.

95 We find here that fluorescently tagged TopoIV (ParC-mKate2) exhibits a
96 localization pattern throughout the cell cycle compatible with the model that TopoIV
97 trails SeqA and the replisome during replication. Moreover, the average distance
98 between TopoIV and the replisome is always larger than that between SeqA and the
99 replisome. This indicates that TopoIV is indeed excluded from binding to the DNA
100 immediately after its replication. Inhibition of TopoIV using a fluoroquinolone
101 antibiotic, Ciprofloxacin, lead to an increased distance between SeqA and TopoIV,
102 presumably because the TopoIV molecules become “stuck” in DNA ternary complexes,
103 thereby lagging even further behind the replication machinery.

104

105 **Results and discussion**

106

107 **TopoIV most likely trails SeqA during DNA replication**


108 In order to investigate the localization of TopoIV with respect to the replication fork and
109 the newly replicated DNA, we constructed a strain which contains fluorescent tags on
110 the single-stranded binding protein (SSB-CFP) present at the replisome, on SeqA
111 (SeqA-YFP) and on TopoIV (ParC-mKate2). The cells exhibited a normal growth rate
112 and cell cycle compared to the wild type background, i.e. they were able to successfully

113 complete DNA replication and had no observable segregation issues (see Table 1 for
114 generation times and cell cycle parameters and Fig S1 for flow cytometry histograms).
115 We grew the cells in poor medium (acetate medium) to early exponential phase
116 (OD~0.15) and investigated the living cells with snap-shot fluorescence microscopy.
117 The images were subjected to analysis with Coli Inspector (see Methods for details) in
118 order to assess the positioning of fluorescent foci. From kymographs of the fluorescent
119 foci (in which the cells are stacked according to cell size) (Fig 1a) and plots of relative
120 fluorescence intensity according to position along the cell long-axis (Fig 1b), we found
121 that TopoIV had a localization pattern that resembled that of SeqA and the replisome.
122 This supports the model that TopoIV trails the replication machinery to ensure
123 processive removal of precatenanes, and that it is not restricted to performing
124 decatenation after replication termination. Flow cytometry analysis of DNA content (as
125 described in ²³) showed that the cells had a cell cycle in which the newborn cell
126 contained one replicating chromosome where the replication forks were about to
127 terminate (see Fig S1 for DNA histograms and schematic cell cycle cartoons). Cells
128 which are about to terminate replication of a chromosome have already segregated their
129 two origins to the respective quarter positions in the cell ^{22,24}. In this study we find that
130 TopoIV is localized at mid-cell at this stage of the cell cycle, i.e. in the newborn cells
131 (Fig 1b top panel). This indicates that TopoIV is not exclusively found in clusters
132 associated with MukB at the origins, as inferred in ^{11,13}. Recently, it was found that the
133 MukB-TopoIV interaction in fact promoted DNA condensation and did not involve any
134 catalytic activity of TopoIV ²⁵. It may therefore be that TopoIV bound to MukB at
135 origins does not contribute to resolution of precatenanes. The reason for the discrepancy
136 between our study and previous studies of TopoIV localization is not known.

137 As observed in previous studies the replisome appears to be more dynamic
138 compared to the replisome-trailing SeqA structures, as one replisome focus more
139 frequently represents one replication fork at each of the quarter positions in cells
140 growing with one replicating chromosome ^{22,26} (see young cells in Fig 1a and b)
141 compared to SeqA which stays at mid cell (thus representing four strands of newly
142 replicated DNA). We found that TopoIV had a localization pattern which was more
143 similar to that of SeqA than to that of the replisome, which is especially prominent in
144 the newborn cells harboring SeqA and TopoIV at midcell (Fig 1b, top panels). This may
145 indicate that TopoIV is closer to SeqA than to the replisome. To further elucidate this
146 scenario we measured the distances between the three fluorescently tagged structures

147 using high-throughput image analysis scripts described previously^{22,24}. Briefly, after
148 processing of the images, the script measures the distances between the highest intensity
149 pixels from each channel/focus, in which the highest concentration of molecules are
150 likely to be situated. From three separate experiments we found that the average
151 distance between SeqA and the replisome was always less than that between TopoIV
152 and the replisome (see average values Fig 1c). This finding suggests that TopoIV binds
153 on the origin-proximal side of SeqA and the replisome (Fig 1d).
154

155 **Figure 1: Fluorescence microscopy indicates that TopoIV trails the replication**
156 **forks and primarily decatenates the precatenanes farthest from the replisome**



157
158 a) Kymographs showing fluorescent foci of TopoIV (ParC-mKate2), SeqA (SeqA-YFP) and replisome
159 (SSB-CFP) in cells stacked horizontally according to cell size (smallest cells top and largest cells bottom).
160 b) Plots of relative fluorescence intensity (Y-axis) according to position on the cell long axis (X-axis) in

161 groups of cell sizes/ages from smallest (top) to largest (bottom). b) Plot showing the average distances
162 (nm) between SeqA-SSB, ParC-SSB and ParC-SeqA in the cells from three independent experiments.
163 Error bars are included in the plot. d) Hypothetical cartoon showing the relative localization of the
164 replisomes (cyan triangles), SeqA molecules (green) and TopoIV molecules (red) on an actively
165 replicating chromosome. The old DNA is shown as black lines, the newly synthesized DNA as grey lines,
166 the origins (*oriCs*) in orange and the terminus region in brown.

167

168 **The distance between SeqA and TopoIV increases when TopoIV is inhibited by** 169 **Ciprofloxacin**

170 The group of antibiotics termed fluoroquinolones is known to bind and inhibit Gyrase
171 and TopoIV by forming a ternary complex with these enzymes and DNA. Upon drug
172 interaction Gyrase/TopoIV remains as a “frozen” adduct on DNA after the cleavage
173 step, and is unable to reseal the double-strand ends after strand passage²⁷. We decided
174 to use the fluoroquinolone Ciprofloxacin to shed more light on the positioning of
175 TopoIV during replication. If TopoIV is localized between the SeqA complex and the
176 replisome, one would expect to observe a perturbation of SeqA focus formation upon
177 inhibition of TopoIV, since SeqA may “collide” into the frozen adducts that occupy the
178 space necessary for SeqA binding and multimerization. If, on the other hand, TopoIV
179 trails SeqA, it would be expected that the distance between the SeqA complex and
180 TopoIV increases compared to the untreated control, as the TopoIV-Ciprofloxacin
181 adducts will be lagging behind on the origin-proximal side of the SeqA complex.

182 To ensure that only TopoIV would be targeted in our experiments, we used a
183 strain which contains two mutations in the GyrA subunit of Gyrase (L83 and Y87)²⁸,
184 rendering Gyrase insensitive to fluoroquinolones, in addition to the fluorescently tagged
185 SeqA (SeqA-YFP) and TopoIV (ParC-mKate2) constructs. The cells were grown in
186 acetate medium to early exponential phase (OD~0.15) and either imaged directly (as
187 described in the previous section) or treated with 0.1 µg/ml Ciprofloxacin for 45
188 minutes prior to imaging.

189 Image analysis showed that the localization pattern of SeqA and TopoIV was
190 different in the Ciprofloxacin-treated cells compared to the untreated control (Fig 2a).
191 This is not surprising, considering that the ability of TopoIV to properly facilitate
192 decatenation and segregation is compromised. However, the Ciprofloxacin-treated cells
193 had no problem with SeqA focus formation, and when measuring the SeqA-TopoIV
194 distances in the cells we found that the average distance was indeed increased in the
195 Ciprofloxacin-treated culture ($r = .70$, $p = .033$) (Fig 2b). A schematic model is depicted

196 in Fig 2c, showing how the Ciprofloxacin-bound TopoIV complexes may become stuck
197 in the DNA and lag behind SeqA, thus leading to an increased SeqA-TopoIV distance.
198 The result supports our previous inferences and strengthens the theory that TopoIV is
199 excluded from the DNA “cohesion window” between SeqA and the replisome.

200 How this cohesion window is maintained is currently not understood. One
201 possible explanation could be that this stretch of DNA is occupied by other proteins,
202 which inhibit TopoIV binding. For instance, high concentrations of SeqA have been
203 shown to inhibit TopoIV activity²⁹, and it has been suggested that SeqA clusters protect
204 the intercatenation linkages from TopoIV⁶. Moreover, an interaction between SeqA and
205 TopoIV has been indicated, and lower concentrations of SeqA seem to stimulate
206 TopoIV activity²⁹. It could therefore be that TopoIV is directed to a DNA region with
207 fewer molecules of SeqA, as indicated in Fig 1d. SeqA plays an important role in
208 regulating the hemimethylation status of newly replicated DNA and it is striking that the
209 period of hemimethylation is similar to that of the cohesion period^{14,15,30}. It could also
210 be that the topology of the precatenated DNA directly behind the replication fork is
211 suboptimal for TopoIV binding.

212 Speculation set aside; there are certainly clear advantages of keeping the newly
213 replicated sister DNA close together for a period of time. It allows for various vital
214 processes to occur due to the proximity of the two homologous double-strands, such as
215 homologous recombination, replication fork remodeling, reversal and restart reactions
216 ^{8,22,31}.

217

218

219

220

221

222

223

224

225


226

227

228

229

230 **Figure 2: Treatment with the antibiotic Ciprofloxacin supports the idea that**
231 **TopoIV activity trails the replication fork on the origin-proximal side of the**
232 **«cohesion window».**



233
234
235 a) Kymographs showing fluorescent foci of TopoIV (ParC-mKate2) and SeqA (SeqA-YFP) in cells
236 stacked horizontally according to cell size (smallest cells top and largest cells bottom). Untreated cells are
237 shown to the left whereas cells treated with Ciprofloxacin (0.1 µg/ml) for 45 minutes are shown to the
238 right. b) Plot showing the average distances (nm) between SeqA and TopoIV (ParC) in untreated (left)
239 and Ciprofloxacin treated (right) cells from three independent experiments. Error bars are included in the
240 plot. The p-value for increase in SeqA-ParC distances in Ciprofloxacin treated cells is indicated in the
241 plot and was calculated using a paired, one-tailed T-test on average distances from three independent
242 experiments. c) Hypothetical cartoon showing how TopoIV (red) may lag farther behind SeqA (green)

243 when inhibited by Ciprofloxacin on the newly replicated DNA. The old DNA is shown as black lines, the
244 newly synthesized DNA as grey lines, the origins (*oriCs*) in orange and the terminus region in brown.

245

246 Tables

247 **Table 1** Cell cycle parameters for strains grown in acetate medium at 28oC (averages
248 from at least three separate experiments +/- SEM)

Strain	Doubling time	C-period	D-period	Initiation
AB1157 Parent	194 +/-26	103 +/-11	122 +/-6	164 +/-47
EH29 SeqA-YFP SSB-CFP ParC-mKate2	184 +/-12	104 +/-10	126 +/-7	139 +/-25
EH32 gyrA ^{L83Y87}	177 +/-42	119 +/-54	73 +/-44	93 +/-92
EH34 SeqA-YFP ParC-mKate2 gyrA ^{L83Y87}	156 +/-36	96 +/-23	86 +/- 11	68 +/-58

249

250 Methods

251 Strain construction: All strains used in experiments are derivatives of the *E. coli* K-12
252 strain AB1157³² and are listed in supplementary Table S1. Localization studies of SeqA
253 were done with cells containing the yellow fluorescent protein (YFP) fused to the C-
254 terminal end of SeqA³³. The *seqA-yfp* gene was expressed from the endogenous
255 chromosomal promoter. The YFP protein was from³⁴ and connected to SeqA via a four-
256 amino acid linker¹⁸. Studies of SSB localization were with cells containing the SSB-
257 CFP allele inserted in place of the *E. coli lamB* gene and was kindly provided by A.
258 Wright (G. Leung et al., unpublished)²². The cells contained the wild-type *ssb* gene on
259 the chromosome. The fluorescent version of ParC was constructed in this study. Briefly,
260 the *mKate2* gene was PCR amplified from the plasmid pTEC20³⁵, subcloned via
261 pGEM-T easy (Promega) and inserted upstream of a chloramphenicol resistance
262 cassette in the plasmid pSF36 (pUC19+cm-FRT-*HindIII*) yielding plasmid pEH04.
263 Primers with 50 bp homology to the C-terminus of *parC* and 50 bp homology to the
264 sequence directly downstream of the *parC* gene were used to amplify *mKate2* with
265 *parC* homology tails from pEH04. These were as follows:

266

267 5'GTGTTGAGATCGACTCTCCTCGCCGTGCCAGCAGCGGTGATAGCGAAGAG
268 TCTGGTTCTGGTTCTGGTTCTGGTTCTGGTTCTGGT
269 GTGAGCGAGCTGATTAAGGAG 3'
270 5'TCATCCGGCGTTCCTTGCAAGCGGGAGGAAACAGCGCCCTCCCCGGCATA
271 TTACGCCAAGCTTGTGTAGGCT 3'

272

273 Next, the PCR-product with flanking tails was electroporated into AB1157 cells, and
274 homologous recombination facilitated by induction of plasmid pRed/ET (GeneBridges)
275 as described in ³⁶.

276 The construct was verified by sequencing to be inserted at the correct position on the
277 chromosome (at the endogenous *parC* gene) and to contain an amino acid linker
278 sequence (Ser-Gly)⁶ between the C-terminal of ParC and the start of mKate2.

279 To obtain the strains used here with combinations of fluorescent constructs and/or
280 mutations, P1 transduction ³⁷ and FLP recombinase (pCP20) was used ³⁸.

281

282 Cell growth: Cells were grown at 28°C in AB minimal medium ³⁹ supplemented with
283 0.4% sodium acetate, 1- $\mu\text{g ml}^{-1}$ thiamine, 80- $\mu\text{g ml}^{-1}$ threonine, 20- $\mu\text{g ml}^{-1}$ leucine, 30-
284 $\mu\text{g ml}^{-1}$ proline, 22- $\mu\text{g ml}^{-1}$ histidine and 22- $\mu\text{g ml}^{-1}$ arginine (acetate medium). The
285 doubling time (τ) was found by optical density (OD) measurements. Cells were grown
286 to OD \sim 0.15 (early exponential phase) at which time they were prepared for flow
287 cytometry analysis or fluorescence microscopy. For experiments with Ciprofloxacin,
288 EH34 cells were treated with 0.1 $\mu\text{g/ml}$ for 45 minutes prior to imaging.

289 Flow cytometry and cell cycle analysis: Exponentially growing cells were fixed in
290 ethanol or treated with 300- $\mu\text{g/ml}$ rifampicin and 10- $\mu\text{g/ml}$ cephalixin to inhibit
291 replication initiation ⁴⁰ and cell division ⁴¹, respectively. Growth of drug-treated samples
292 continued for 3–4 generations, after which they were fixed in ethanol. Drug-treated cells
293 ended up with an integral number of chromosomes ⁴⁰, which represents the number of
294 origins at the time of drug treatment (replication run-out). Flow cytometry was
295 performed as previously described ⁴² using an LSR II flow cytometer (BD Biosciences)
296 and FlowJo 7.2.5 software. Cell cycle parameters, numbers of origins and replication
297 forks per cell were obtained by analysis of the DNA distributions obtained by flow
298 cytometry as described ²³.

299 Fluorescence microscopy imaging: for fluorescence microscopy exponentially growing
300 cells were immobilized on an agarose pad (1% agarose in phosphate-buffered saline)
301 and covered with a #1.5 coverslip. Images were acquired with a Leica DM6000
302 microscope equipped with a Leica EL6000 metal halide lamp and a Leica DFC350 FX
303 monochrome CCD camera. Phase contrast imaging was performed with an HCX
304 PLAPO 100x/1.40 NA objective. Narrow band-pass filter sets (CFP: Ex BP436/20, Em
305 BP480/40, YFP: Ex BP510/20, Em BP560/40, Cy3: Ex BP545/30, Em BP610/75) were
306 used for fluorescence imaging.

307 During image acquisition, saturated pixels were avoided. The raw images were saved
308 for further image processing (see below).

309 Image processing and analysis: imaging adjustments (brightness and contrast) were
310 performed in Image J or Fiji software. We used the public domain Coli-Inspector
311 project to obtain fluorescence intensity profiles of the cells and to do vertical plotting of
312 fluorescence and phase contrast images of cells. Coli-Inspector runs under ImageJ/Fiji
313 in combination with the plugin ObjectJ (<http://simon.bio.uva.nl/objectj/>). The average
314 fluorescence intensity profile of cells was plotted against the cell long axis, in groups of
315 increasing cell length, as described ⁴³. Vertical plotting of cells was done in the order of
316 gradual increase in cell length. Age classes of cells were defined by the cell length,
317 assuming that length increases linearly.

318 We used a Python-based script developed in our group for measurements of distances
319 between neighboring spots/foci that are registered in two different fluorescence
320 channels. The script outputs all registered distances (in this case distances between
321 SeqA, ParC and SSB) per cell, and these values were used to calculate average distances
322 from at least three separate experiments. Image processing for automated analysis using
323 this script was performed in Image J using the following tools: i) Background
324 subtraction with default Rolling disk (diameter 10 pixels), ii) Deconvolution using the
325 Richardson-Lucy algorithm (100 iterations), iii) Median filter, iv) thresholding by Max
326 Entropy (see ²² for details). The positive correlation and p-value for increase in SeqA-
327 ParC distances in Ciprofloxacin treated cells was calculated using a paired, one-tailed T-
328 test on average distances from three independent experiments.

329

330

331

332 Reference List

333

- 334 1 Koster, D. A., Crut, A., Shuman, S., Bjornsti, M. A. & Dekker, N. H. Cellular
335 strategies for regulating DNA supercoiling: a single-molecule perspective. *Cell*
336 **142**, 519-530, doi:10.1016/j.cell.2010.08.001 (2010).
- 337 2 Vos, S. M., Tretter, E. M., Schmidt, B. H. & Berger, J. M. All tangled up: how cells
338 direct, manage and exploit topoisomerase function. *Nature reviews. Molecular*
339 *cell biology* **12**, 827-841, doi:10.1038/nrm3228 (2011).
- 340 3 Cebrian, J. *et al.* Direct Evidence for the Formation of Precatenanes during DNA
341 Replication. *The Journal of biological chemistry* **290**, 13725-13735,
342 doi:10.1074/jbc.M115.642272 (2015).
- 343 4 Peter, B. J., Ullsperger, C., Hiasa, H., Marians, K. J. & Cozzarelli, N. R. The
344 structure of supercoiled intermediates in DNA replication. *Cell* **94**, 819-827
345 (1998).
- 346 5 Schoeffler, A. J. & Berger, J. M. DNA topoisomerases: harnessing and
347 constraining energy to govern chromosome topology. *Quarterly reviews of*
348 *biophysics* **41**, 41-101, doi:10.1017/s003358350800468x (2008).
- 349 6 Joshi, M. C. *et al.* Regulation of sister chromosome cohesion by the replication
350 fork tracking protein SeqA. *PLoS genetics* **9**, e1003673,
351 doi:10.1371/journal.pgen.1003673 (2013).
- 352 7 Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. Topoisomerase IV is a
353 target of quinolones in *Escherichia coli*. *Proceedings of the National Academy of*
354 *Sciences of the United States of America* **92**, 11801-11805 (1995).
- 355 8 Lesterlin, C., Gigant, E., Boccard, F. & Espeli, O. Sister chromatid interactions in
356 bacteria revealed by a site-specific recombination assay. *The EMBO journal* **31**,
357 3468-3479, doi:10.1038/emboj.2012.194 (2012).
- 358 9 Wang, X., Reyes-Lamothe, R. & Sherratt, D. J. Modulation of *Escherichia coli*
359 sister chromosome cohesion by topoisomerase IV. *Genes & development* **22**,
360 2426-2433, doi:10.1101/gad.487508 (2008).
- 361 10 Espeli, O., Levine, C., Hassing, H. & Marians, K. J. Temporal regulation of
362 topoisomerase IV activity in *E. coli*. *Molecular cell* **11**, 189-201 (2003).
- 363 11 Nicolas, E. *et al.* The SMC complex MukBEF recruits topoisomerase IV to the
364 origin of replication region in live *Escherichia coli*. *mBio* **5**, e01001-01013,
365 doi:10.1128/mBio.01001-13 (2014).
- 366 12 Nolivos, S. *et al.* MatP regulates the coordinated action of topoisomerase IV
367 and MukBEF in chromosome segregation. *Nature Communications* **7**, 10466,
368 doi:10.1038/ncomms10466 (2016).
- 369 13 Zawadzki, P. *et al.* The Localization and Action of Topoisomerase IV in
370 *Escherichia coli* Chromosome Segregation Is Coordinated by the SMC Complex,
371 MukBEF. *Cell reports* **13**, 2587-2596, doi:10.1016/j.celrep.2015.11.034 (2015).
- 372 14 Nielsen, H. J., Li, Y., Youngren, B., Hansen, F. G. & Austin, S. Progressive
373 segregation of the *Escherichia coli* chromosome. *Molecular microbiology* **61**,
374 383-393, doi:10.1111/j.1365-2958.2006.05245.x (2006).
- 375 15 Campbell, J. L. & Kleckner, N. *E. coli oriC* and the *dnaA* gene promoter are
376 sequestered from dam methyltransferase following the passage of the
377 chromosomal replication fork. *Cell* **62**, 967-979 (1990).

- 378 16 Lu, M., Campbell, J. L., Boye, E. & Kleckner, N. SeqA: a negative modulator of
379 replication initiation in *E. coli*. *Cell* **77**, 413-426 (1994).
- 380 17 von Freiesleben, U., Rasmussen, K. V. & Schaechter, M. SeqA limits DnaA
381 activity in replication from *oriC* in *Escherichia coli*. *Molecular microbiology* **14**,
382 763-772 (1994).
- 383 18 Fossum-Raunehaug, S., Helgesen, E., Stokke, C. & Skarstad, K. *Escherichia coli*
384 SeqA structures relocalize abruptly upon termination of origin sequestration
385 during multifork DNA replication. *PloS one* **9**, e110575,
386 doi:10.1371/journal.pone.0110575 (2014).
- 387 19 Molina, F. & Skarstad, K. Replication fork and SeqA focus distributions in
388 *Escherichia coli* suggest a replication hyperstructure dependent on nucleotide
389 metabolism. *Molecular microbiology* **52**, 1597-1612, doi:10.1111/j.1365-
390 2958.2004.04097.x (2004).
- 391 20 Odsbu, I., Morigen & Skarstad, K. A Reduction in Ribonucleotide Reductase
392 Activity Slows Down the Chromosome Replication Fork but Does Not Change Its
393 Localization. *PloS one* **4**, doi:10.1371/journal.pone.0007617 (2009).
- 394 21 Waldminghaus, T., Weigel, C. & Skarstad, K. Replication fork movement and
395 methylation govern SeqA binding to the *Escherichia coli* chromosome. *Nucleic*
396 *acids research* **40**, 5465-5476, doi:10.1093/nar/gks187 (2012).
- 397 22 Helgesen, E., Fossum-Raunehaug, S., Sætre, F., Schink, K. O. & Skarstad, K.
398 Dynamic *Escherichia coli* SeqA complexes organize the newly replicated DNA at
399 a considerable distance from the replisome. *Nucleic acids research* **43**, 2730-
400 2743, doi:10.1093/nar/gkv146 (2015).
- 401 23 Stokke, C., Flåtten, I. & Skarstad, K. An easy-to-use simulation program
402 demonstrates variations in bacterial cell cycle parameters depending on
403 medium and temperature. *PloS one* **7**, e30981,
404 doi:10.1371/journal.pone.0030981 (2012).
- 405 24 Helgesen, E., Fossum-Raunehaug, S. & Skarstad, K. Lack of the H-NS Protein
406 Results in Extended and Aberrantly Positioned DNA during Chromosome
407 Replication and Segregation in *Escherichia coli*. *Journal of bacteriology* **198**,
408 1305-1316, doi:10.1128/jb.00919-15 (2016).
- 409 25 Kumar, R., Nurse, P., Bahng, S., Lee, C. M. & Mariani, K. J. The MukB-
410 topoisomerase IV interaction is required for proper chromosome compaction.
411 *The Journal of biological chemistry* **292**, 16921-16932,
412 doi:10.1074/jbc.M117.803346 (2017).
- 413 26 Reyes-Lamothe, R., Possoz, C., Danilova, O. & Sherratt, D. J. Independent
414 Positioning and Action of *Escherichia coli* Replisomes in Live Cells. *Cell* **133**, 90-
415 102, doi:10.1016/j.cell.2008.01.044 (2008).
- 416 27 Hooper, D. C. & Jacoby, G. A. Topoisomerase Inhibitors: Fluoroquinolone
417 Mechanisms of Action and Resistance. *Cold Spring Harbor perspectives in*
418 *medicine* **6**, doi:10.1101/cshperspect.a025320 (2016).
- 419 28 Morgan-Linnell, S. K. & Zechiedrich, L. Contributions of the combined effects of
420 topoisomerase mutations toward fluoroquinolone resistance in *Escherichia coli*.
421 *Antimicrobial agents and chemotherapy* **51**, 4205-4208,
422 doi:10.1128/aac.00647-07 (2007).
- 423 29 Kang, S., Han, J. S., Park, J. H., Skarstad, K. & Hwang, D. S. SeqA protein
424 stimulates the relaxing and decatenating activities of topoisomerase IV. *The*

- 425 *Journal of biological chemistry* **278**, 48779-48785, doi:10.1074/jbc.M308843200
426 (2003).
- 427 30 Joshi, M. C. *et al.* *Escherichia coli* sister chromosome separation includes an
428 abrupt global transition with concomitant release of late-splitting intersister
429 snaps. *Proceedings of the National Academy of Sciences of the United States of*
430 *America* **108**, 2765-2770, doi:10.1073/pnas.1019593108 (2011).
- 431 31 Michel, B., Sinha, A. K. & Leach, D. R. F. Replication Fork Breakage and Restart
432 in *Escherichia coli*. *Microbiology and Molecular Biology Reviews : MMBR* **82**,
433 doi:10.1128/mmbr.00013-18 (2018).
- 434 32 Howard-Flanders, P., Simson, E. & Theriot, L. A locus that controls filament
435 formation and sensitivity to radiation in *Escherichia coli* K-12. *Genetics* **49**, 237-
436 246 (1964).
- 437 33 Babic, A., Lindner, A. B., Vulic, M., Stewart, E. J. & Radman, M. Direct
438 visualization of horizontal gene transfer. *Science (New York, N.Y.)* **319**, 1533-
439 1536, doi:10.1126/science.1153498 (2008).
- 440 34 Lindner, A. B., Madden, R., Demarez, A., Stewart, E. J. & Taddei, F. Asymmetric
441 segregation of protein aggregates is associated with cellular aging and
442 rejuvenation. *Proceedings of the National Academy of Sciences of the United*
443 *States of America* **105**, 3076-3081, doi:10.1073/pnas.0708931105 (2008).
- 444 35 Takaki, K., Davis, J. M., Winglee, K. & Ramakrishnan, L. Evaluation of the
445 pathogenesis and treatment of *Mycobacterium marinum* infection in zebrafish.
446 *Nature protocols* **8**, 1114-1124, doi:10.1038/nprot.2013.068 (2013).
- 447 36 Sawitzke, J. A. *et al.* Recombineering: in vivo genetic engineering in *E. coli*, *S.*
448 *enterica*, and beyond. *Methods in enzymology* **421**, 171-199,
449 doi:10.1016/s0076-6879(06)21015-2 (2007).
- 450 37 Miller, J. H. *A short course in bacterial genetics*. (Cold Spring Harbor Laboratory
451 Press, 1992).
- 452 38 Cherepanov, P. P. & Wackernagel, W. Gene disruption in *Escherichia coli*: TcR
453 and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-
454 resistance determinant. *Gene* **158**, 9-14, doi:10.1016/0378-1119(95)00193-a
455 (1995).
- 456 39 Clark, D. J. & Maaløe, O. DNA replication and the division cycle in *Escherichia*
457 *coli*. *J Mol* **23**, 99-112 (1967).
- 458 40 Skarstad, K., Boye, E. & Steen, H. B. Timing of initiation of chromosome
459 replication in individual *Escherichia coli* cells. *The EMBO journal* **5**, 1711-1717
460 (1986).
- 461 41 Boye, E. & Lobner-Olesen, A. Bacterial growth control studied by flow
462 cytometry. *Research in microbiology* **142**, 131-135 (1991).
- 463 42 Torheim, N. K., Boye, E., Lobner-Olesen, A., Stokke, T. & Skarstad, K. The
464 *Escherichia coli* SeqA protein destabilizes mutant DnaA204 protein. *Molecular*
465 *microbiology* **37**, 629-638 (2000).
- 466 43 Potluri, L. *et al.* Septal and lateral wall localization of PBP5, the major D,D-
467 carboxypeptidase of *Escherichia coli*, requires substrate recognition and
468 membrane attachment. *Molecular microbiology* **77**, 300-323,
469 doi:10.1111/j.1365-2958.2010.07205.x (2010).
- 470
471

472

473 **Acknowledgements**

474 We thank A. Wahl for excellent technical assistance, B. Sen for construction of strains
475 and S. Fossum-Raunehaug for the plasmid pSF36. The Flow Cytometry Core Facility
476 (by T. Stokke) at The Norwegian Radium Hospital is greatly acknowledged for help
477 with flow cytometry analysis. We thank A. Wright, M. Radman and L. Zechiedrich for
478 providing strains. This work was supported by a grant from Helse Sør-Øst (project
479 2012062).

480 **Author contributions**

481 Conceived and developed the study: E.H., F.S., K.S. Performed the experiments and
482 analyzed the data: E.H., F.S. Interpreted the results: E.H., K.S. Wrote the manuscript:
483 E.H., K.S.

484 **Competing interests**

485 The authors declare no competing interests.

486